Phase I Study of Azacitidine following Donor Lymphocyte Infusion for Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation

Donor lymphocyte infusion (DLI) without prophylactic immunosuppression has been used for relapsed AML after allogeneic stem cell transplant (allo-SCT). However DLI is associated with an increased incidence of acute Graft vs. Host Disease (aGVHD). In mice, administration of azacitidine (AzaC) on days...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Res
Autori principali: Ghobadi, Armin, Choi, Jaebok, Fiala, Mark A., Fletcher, Theresa, Liu, Jingxia, Eissenberg, Linda G., Abboud, Camille, Cashen, Amanda, Vij, Ravi, Schroeder, Mark A., Pusic, Iskra, Stockerl-Goldstein, Keith, Jacoby, Meagan, Uy, Geoffrey, DiPersio, John, Westervelt, Peter
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5037011/
https://ncbi.nlm.nih.gov/pubmed/27505705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2016.07.010
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi